Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
Conference Call and Webcast to Be Held Tuesday, April 2, 2019 at 8:00 am ET / 1:00 pm BST
UCLB spinout, Autolus Therapeutics, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that management will host a conference call and webcast on Tuesday, April 2, 2019 at 8:00 am ET / 1:00 pm BST to discuss initial data on the AUTO1 ALLCAR19 Phase 1/2 trial in adult acute lymphoblastic leukemia (ALL) being presented at the American Association of Cancer Research (AACR) Annual Meeting on April 1, 2019 in Atlanta, Georgia.
Founded in 2014, Autolus is based on the advanced T cell programming technology pioneered by Dr Martin Pule of the UCL Cancer Institute.
Read more here: Autolus Therapeutics